MS
SRPT icon

Maven Securities’s Sarepta Therapeutics SRPT Stock Holding History

Maven Securities’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,423
Closed -$892K – 1088
2022
Q1 		$892K Buy
+11,423
New +$875K 0.03% 380
2018
Q4 		– Sell
-1,500
Closed -$240K – 162
2018
Q3 		$240K Buy
+1,500
New +$205K 0.09% 132

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Maven Securities's SRPT Position: Q2 2022 in Review

Maven Securities sold out of Sarepta Therapeutics (SRPT) in Q2 2022, closing a stake of 11,423 shares — an estimated $892K sold.

Maven Securities first reported a position in SRPT in Q3 2018 and held it in 2 quarters. The position peaked at $892K in Q1 2022. 331 funds tracked by Wall St. Rank hold SRPT as of Q2 2022.

  • Maven Securities reported no remaining Sarepta Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Maven Securities sold 11,423 Sarepta Therapeutics shares in Q2 2022, an estimated $892K.
  • Maven Securities first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 2 quarters.
  • Maven Securities's Sarepta Therapeutics position peaked at $892K in Q1 2022.
  • 331 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2022.

Based on Maven Securities's 13F filing for Q2 2022, filed 15 Aug 2022.